Logo

Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson's Disease in Canada

Share this

Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson's Disease in Canada

Shots:

  • The launch of Onstryv follows its Health Canada approval received on Jan 15- 2019 as an add-on therapy to a levodopa regimen indicated to treat signs and symptoms of idiopathic Parkinson’s disease in patients with off episodes
  • Valeo Pharma has exclusive rights for Onstryv and is responsible for all regulatory- quality- commercialization and distribution activities in Canada under an agreement with Zambon signed on Apr’2017
  • Onstryv (marketed as Xadago in ROW) is an oral- selective & reversible MAO-B-inhibitor- available in Canadian pharmacies as 50mg & 100mg tablets

Click here to read full press release/ article | Ref: Business Wire | Image: LinkedIn


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions